BTT vs MESO Comparison

Blackrock Municipal 2030 Target Term Trust is a United States-based closed-end management investment company. The investment objective of the company is to provide current income exempt from regular federal income tax and to return $25.00 per common share to holders of common shares. The trust seeks to achieve its investment objectives by investing a majority of its assets in municipal bonds exempt from U.S. federal income taxes.

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.